	US 12,109,381 B2
	Cannabinoid and menthol transdermal delivery systems and methods
Babak Ghalili, New York, NY (US); John Borja, Keyport, NJ (US); and Arthur Goldberg, Livingston, NJ (US)
Filed by Babak Ghalili, New York, NY (US); John Borja, Keyport, NJ (US); and Arthur Goldberg, Livingston, NJ (US)
Filed on Aug. 26, 2021, as Appl. No. 17/412,442.
Claims priority of provisional application 63/070,554, filed on Aug. 26, 2020.
Prior Publication US 2022/0062603 A1, Mar. 3, 2022
Int. Cl. A61M 37/00 (2006.01); A61K 9/70 (2006.01); A61K 31/045 (2006.01); A61K 45/06 (2006.01); A61K 47/14 (2017.01); A61K 47/20 (2006.01)

CPC A61M 37/00 (2013.01) [A61K 9/7023 (2013.01); A61K 31/045 (2013.01); A61K 45/06 (2013.01); A61K 47/14 (2013.01); A61K 47/20 (2013.01); A61K 9/7084 (2013.01); A61M 2037/0007 (2013.01); A61M 2205/0233 (2013.01); A61M 2205/055 (2013.01)]

20 Claims

1. A transdermal delivery system, comprising:

a first hydrogel reservoir and a second hydrogel reservoir separated from each other, one of the first hydrogel reservoir and the second hydrogel reservoir including a mixture of an anionic or cationic surfactant, DMSO and at least one cannabinoid, and a stabilized menthol composition for lowering the rate of volatilization of menthol, the stabilized menthol composition including a pre-formed mixture consisting essentially of menthol and a menthol stabilizer compound including undecylenic acid methyl ester wherein the stabilized menthol composition is formed and encapsulated in a cyclodextrin prior to being added to the mixture of the anionic or cationic surfactant, DMSO and the at least one cannabinoid; and

a circuit apparatus including a power source, the circuit apparatus configured to supply power to the first hydrogel reservoir and the second hydrogel reservoir.